Literature DB >> 12895227

Prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma of the endometrium.

Chikako Suzuki1, Toshiharu Matsumoto, Hiroshi Sonoue, Atsushi Arakawa, Yoshiaki Furugen, Katsuyuki Kinoshita.   

Abstract

The prognostic significance of the invasive type of carcinoma cells in endometrial carcinoma is not defined. We evaluated the prognostic significance of the invasive type, as well as the immunostains of p53, c-erbB-2, Ki-67 antigen and MDM2 in endometrial endometrioid adenocarcinoma. This prospective analysis comprised 112 patients with endometrioid adenocarcinoma of the uterine corpus who had undergone surgery and were traced for more than 5 years after the operation. They were divided into recurrence (16 patients) and non-recurrence (96 patients) groups. The invasive type of carcinoma cells was divided into expansile, mixed (expansile and infiltrative) and infiltrative pattern. The difference in the invasive type (P < 0.001) and p53 expression (P = 0.004) between the recurrence and non-recurrence groups was significant in the univariate analysis. Moreover, the invasive type was significant in the multivariate analysis (P = 0.004). In contrast, the difference in MDM2 expression, c-erbB-2 expression and the Ki-67 labeling index in both groups was not significant in the univariate analysis. The infiltrative pattern of the invasive type (P < 0.001) and p53 expression (P = 0.043) were significantly related to a poor prognosis in the Kaplan-Meier method using the log-rank test. In conclusion, the current study indicated that the infiltrative pattern of the carcinoma cells is a predictor for poor prognosis in endometrioid adenocarcinoma in the uterine corpus. It was also indicated that p53 immunostains are useful as a predictor, but Ki-67 antigen, c-erbB-2 and MDM2 stains are not.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895227     DOI: 10.1046/j.1440-1827.2003.01509.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  6 in total

1.  P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome.

Authors:  Ryszard Jeczen; Danuta Skomra; Marek Cybulski; Regine Schneider-Stock; Wiktor Szewczuk; Albert Roessner; Tomasz Rechberger; Andrzej Semczuk
Journal:  Clin Exp Metastasis       Date:  2007-08-02       Impact factor: 4.510

2.  Analysis of the invasive edge in primary and secondary oral squamous cell carcinoma: An independent prognostic marker: A retrospective study.

Authors:  Afreen Nadaf; Radhika M Bavle; M Soumya; Sarah D'mello; Moni Abraham Kuriakose; Sindhu Govindan
Journal:  J Oral Maxillofac Pathol       Date:  2016 May-Aug

Review 3.  The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.

Authors:  Mitsuhiro Nakamura; Takeshi Obata; Takiko Daikoku; Hiroshi Fujiwara
Journal:  Int J Mol Sci       Date:  2019-11-04       Impact factor: 5.923

4.  Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma.

Authors:  Ignacio Ruz-Caracuel; Jorge L Ramón-Patino; Álvaro López-Janeiro; Laura Yébenes; Alberto Berjón; Alicia Hernández; Alejandro Gallego; Victoria Heredia-Soto; Marta Mendiola; Andrés Redondo; Alberto Peláez-García; David Hardisson
Journal:  Cancers (Basel)       Date:  2019-11-22       Impact factor: 6.639

5.  The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas.

Authors:  Aylin Ege Gul; Sevinc Hallac Keser; Nagehan Ozdemir Barisik; Nilufer Onak Kandemir; Caglar Cakir; Sibel Sensu; Nimet Karadayi
Journal:  Diagn Pathol       Date:  2010-02-18       Impact factor: 2.644

6.  Significantly decreased P27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression).

Authors:  Sevgiye Kacar Ozkara; Aydin Corakci
Journal:  Pathol Oncol Res       Date:  2004-06-09       Impact factor: 2.874

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.